{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T05:15:35Z","timestamp":1792818935225,"version":"4.5.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06114-6","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T01:26:00Z","timestamp":1751419560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Assessment of drug induced hyperuricemia and gout risk using the FDA adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"given":"Guihao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meifeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guicai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"3","key":"6114_CR1","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jbspin.2015.01.002","volume":"82","author":"T Bardin","year":"2015","unstructured":"Bardin, T. Hyperuricemia starts at 360 micromoles (6\u00a0mg\/dL). Joint Bone Spine. 82(3), 141\u2013143 (2015).","journal-title":"Joint Bone Spine"},{"issue":"3","key":"6114_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1007\/s10067-024-06891-x","volume":"43","author":"SW Lai","year":"2024","unstructured":"Lai, S. W., Hwang, B. F., Kuo, Y. H., Liu, C. S. & Liao, K. F. Risk of gout flare after medication: Prescription symmetry sequence analysis. Clin. Rheumatol. 43(3), 1183\u20131188 (2024).","journal-title":"Clin. Rheumatol."},{"key":"6114_CR3","doi-asserted-by":"crossref","unstructured":"Yanai, H., Adachi, H., Hakoshima, M. & Katsuyama, H. Molecular biological and clinical Understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. International J. Mol. Sciences 22(17). (2021).","DOI":"10.3390\/ijms22179221"},{"issue":"6","key":"6114_CR4","doi-asserted-by":"publisher","first-page":"700","DOI":"10.2174\/1381612825666190408122557","volume":"25","author":"S Zhang","year":"2019","unstructured":"Zhang, S. et al. Hyperuricemia and cardiovascular disease. Curr. Pharm. Design. 25(6), 700\u2013709 (2019).","journal-title":"Curr. Pharm. Design"},{"issue":"5","key":"6114_CR5","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1001\/jama.2022.11390","volume":"328","author":"E Cipolletta","year":"2022","unstructured":"Cipolletta, E. et al. Association between gout flare and subsequent cardiovascular events among patients with gout. Jama 328(5), 440\u2013450 (2022).","journal-title":"Jama"},{"key":"6114_CR6","doi-asserted-by":"crossref","unstructured":"Challener, G. & Yokose, C. Year in Review 2023: Gout Clinical Research. In: Gout, Urate, and Crystal Deposition Disease. vol. 2; : 354\u2013369. (2024).","DOI":"10.3390\/gucdd2040025"},{"key":"6114_CR7","doi-asserted-by":"crossref","unstructured":"Bardin, T., Letavernier, E. & Correas, J-M. The Gouty Kidney: A Reappraisal. In: Gout, Urate, and Crystal Deposition Disease. vol. 1; : 25\u201336. (2023).","DOI":"10.3390\/gucdd1010004"},{"key":"6114_CR8","doi-asserted-by":"crossref","unstructured":"Andr\u00e9s, M. Gout and Cardiovascular Disease: Mechanisms, Risk Estimations, and the Impact of Therapies. In: Gout, Urate, and Crystal Deposition Disease. vol. 1; : 152\u2013166. (2023).","DOI":"10.3390\/gucdd1030014"},{"issue":"10287","key":"6114_CR9","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth, N., Gosling, A. L., Gaffo, A., Abhishek, A. & Gout Lancet (London England) 397(10287):1843\u20131855. (2021).","journal-title":"Lancet (London England)"},{"issue":"4","key":"6114_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41584-025-01228-7","volume":"21","author":"B G\u00e9rard","year":"2025","unstructured":"G\u00e9rard, B. et al. Hyperuricaemia and gout in the Pacific. Nat. Rev. Rheumatol. 21(4), 197\u2013210 (2025).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"4","key":"6114_CR11","doi-asserted-by":"publisher","first-page":"e685","DOI":"10.1016\/S2214-109X(24)00012-3","volume":"12","author":"T Pascart","year":"2024","unstructured":"Pascart, T. et al. The gout epidemic in French polynesia: A modelling study of data from the ma\u2019i u\u2019u epidemiological survey. Lancet Global Health. 12(4), e685\u2013e696 (2024).","journal-title":"Lancet Global Health"},{"issue":"11","key":"6114_CR12","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/nrrheum.2015.91","volume":"11","author":"CF Kuo","year":"2015","unstructured":"Kuo, C. F., Grainge, M. J., Zhang, W. & Doherty, M. Global epidemiology of gout: Prevalence, incidence and risk factors. Nat. Rev. Rheumatol. 11(11), 649\u2013662 (2015).","journal-title":"Nat. Rev. Rheumatol."},{"issue":"Suppl 2","key":"6114_CR13","doi-asserted-by":"publisher","first-page":"ii2","DOI":"10.1093\/rheumatology\/kep086","volume":"48","author":"M Doherty","year":"2009","unstructured":"Doherty, M. New insights into the epidemiology of gout. Rheumatol. (Oxford England). 48(Suppl 2), ii2\u2013ii8 (2009).","journal-title":"Rheumatol. (Oxford England)"},{"issue":"6","key":"6114_CR14","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/art.40807","volume":"71","author":"M Chen-Xu","year":"2019","unstructured":"Chen-Xu, M., Yokose, C., Rai, S. K., Pillinger, M. H. & Choi, H. K. Contemporary prevalence of gout and hyperuricemia in the united States and decadal trends: the National health and nutrition examination survey, 2007\u20132016. Arthritis Rheumatol. (Hoboken NJ). 71(6), 991\u2013999 (2019).","journal-title":"Arthritis Rheumatol. (Hoboken NJ)"},{"issue":"10055","key":"6114_CR15","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth, N., Merriman, T. R., Stamp, L. K. & Gout Lancet (London England) 388(10055):2039\u20132052. (2016).","journal-title":"Lancet (London England)"},{"issue":"1","key":"6114_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","volume":"5","author":"N Dalbeth","year":"2019","unstructured":"Dalbeth, N. et al. Gout. Nat. Reviews Disease Primers. 5(1), 69 (2019).","journal-title":"Nat. Reviews Disease Primers"},{"issue":"5","key":"6114_CR17","first-page":"679","volume":"56","author":"C Ben Salem","year":"2017","unstructured":"Ben Salem, C., Slim, R., Fathallah, N. & Hmouda, H. Drug-induced hyperuricaemia and gout. Rheumatol. (Oxford England). 56(5), 679\u2013688 (2017).","journal-title":"Rheumatol. (Oxford England)"},{"issue":"8","key":"6114_CR18","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/ard.2005.040360","volume":"65","author":"HJ Janssens","year":"2006","unstructured":"Janssens, H. J., van de Lisdonk, E. H., Janssen, M., van den Hoogen, H. J. & Verbeek, A. L. Gout, not induced by diuretics? A case-control study from primary care. Ann. Rheum. Dis. 65(8), 1080\u20131083 (2006).","journal-title":"Ann. Rheum. Dis."},{"issue":"8","key":"6114_CR19","first-page":"e5457","volume":"11","author":"R Raja","year":"2019","unstructured":"Raja, R. et al. Hyperuricemia associated with Thiazide diuretics in hypertensive adults. Cureus 11(8), e5457 (2019).","journal-title":"Cureus"},{"issue":"2","key":"6114_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1001\/jama.1970.03170020041008","volume":"211","author":"HE Paulus","year":"1970","unstructured":"Paulus, H. E., Coutts, A., Calabro, J. J. & Klinenberg, J. R. Clinical significance of hyperuricemia in routinely screened hospitalized men. Jama 211(2), 277\u2013281 (1970).","journal-title":"Jama"},{"key":"6114_CR21","unstructured":"Elisabetta, P., Emanuel, R., Carlo, P. & Fabrizio De, P. Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). In: Data Mining Applications in Engineering and Medicine. Edited by Adem K. Rijeka: IntechOpen; : Ch. 12. (2012)."},{"issue":"Suppl 5","key":"6114_CR22","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.3949\/ccjm.75.Suppl_5.S2","volume":"75","author":"HR Schumacher Jr","year":"2008","unstructured":"Schumacher, H. R. Jr. The pathogenesis of gout. Cleve. Clin. J. Med. 75(Suppl 5), S2\u20134 (2008).","journal-title":"Cleve. Clin. J. Med."},{"key":"6114_CR23","doi-asserted-by":"crossref","unstructured":"Li, R., Liang, N., Tao, Y. & Yin, H. Metabolomics in Hyperuricemia and Gout. In: Gout, Urate, and Crystal Deposition Disease. vol. 1; : 49\u201361. (2023).","DOI":"10.3390\/gucdd1010006"},{"issue":"8","key":"6114_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41584-024-01137-1","volume":"20","author":"MP Leask","year":"2024","unstructured":"Leask, M. P. et al. The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies. Nat. Rev. Rheumatol. 20(8), 510\u2013523 (2024).","journal-title":"Nat. Rev. Rheumatol."},{"key":"6114_CR25","doi-asserted-by":"crossref","unstructured":"Takada, T. et al. Regulation of Urate Homeostasis by Membrane Transporters. In: Gout, Urate, and Crystal Deposition Disease. vol. 2; : 206\u2013219. (2024).","DOI":"10.3390\/gucdd2020016"},{"key":"6114_CR26","doi-asserted-by":"crossref","unstructured":"King, R. D. & Kelley, E. E. Urate Biology and Biochemistry: A Year in Review 2022. In: Gout, Urate, and Crystal Deposition Disease. vol. 1; : 115\u2013121. (2023).","DOI":"10.3390\/gucdd1030011"},{"issue":"1","key":"6114_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.rdc.2013.10.004","volume":"40","author":"V Bhole","year":"2014","unstructured":"Bhole, V. & Krishnan, E. Gout and the heart. Rheum. Dis. Clin. North Am. 40(1), 125\u2013143 (2014).","journal-title":"Rheum. Dis. Clin. North Am."},{"key":"6114_CR28","doi-asserted-by":"crossref","unstructured":"Gupta, S. et al. The Risk of Cardiovascular Disease among Male and Female Participants Treated for Gout in the Multi-Ethnic Study of Atherosclerosis (MESA). In: Gout, Urate, and Crystal Deposition Disease. vol. 1; : 89\u201398. (2023).","DOI":"10.3390\/gucdd1020009"},{"issue":"4","key":"6114_CR29","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","volume":"37","author":"KB Hoffman","year":"2014","unstructured":"Hoffman, K. B., Dimbil, M., Erdman, C. B., Tatonetti, N. P. & Overstreet, B. M. The Weber effect and the united States food and drug administration\u2019s adverse event reporting system (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 37(4), 283\u2013294 (2014).","journal-title":"Drug Saf."},{"key":"6114_CR30","doi-asserted-by":"publisher","first-page":"989032","DOI":"10.3389\/fphar.2022.989032","volume":"13","author":"T Jiang","year":"2022","unstructured":"Jiang, T. et al. Post-marketing safety of Immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system. Front. Pharmacol. 13, 989032 (2022).","journal-title":"Front. Pharmacol."},{"issue":"8","key":"6114_CR31","doi-asserted-by":"publisher","first-page":"e2226804","DOI":"10.1001\/jamanetworkopen.2022.26804","volume":"5","author":"N McCormick","year":"2022","unstructured":"McCormick, N. et al. Racial and sex disparities in gout prevalence among US adults. JAMA Netw. Open. 5(8), e2226804 (2022).","journal-title":"JAMA Netw. Open."},{"key":"6114_CR32","doi-asserted-by":"publisher","first-page":"e45943","DOI":"10.2196\/45943","volume":"9","author":"Q He","year":"2023","unstructured":"He, Q. et al. Global, regional, and National prevalence of gout from 1990 to 2019: Age-Period-Cohort analysis with future burden prediction. JMIR Public. Health Surveillance. 9, e45943 (2023).","journal-title":"JMIR Public. Health Surveillance"},{"issue":"7","key":"6114_CR33","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1136\/ard.2009.109884","volume":"69","author":"AE Hak","year":"2010","unstructured":"Hak, A. E., Curhan, G. C., Grodstein, F. & Choi, H. K. Menopause, postmenopausal hormone use and risk of incident gout. Ann. Rheum. Dis. 69(7), 1305\u20131309 (2010).","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"6114_CR34","doi-asserted-by":"publisher","first-page":"e239501","DOI":"10.1001\/jamanetworkopen.2023.9501","volume":"6","author":"C Yokose","year":"2023","unstructured":"Yokose, C. et al. Trends in prevalence of gout among US Asian adults, 2011\u20132018. JAMA Netw. Open. 6(4), e239501 (2023).","journal-title":"JAMA Netw. Open."},{"key":"6114_CR35","doi-asserted-by":"publisher","first-page":"1759720x2096612","DOI":"10.1177\/1759720X20966124","volume":"12","author":"JA Singh","year":"2020","unstructured":"Singh, J. A. & Edwards, N. L. Gout management and outcomes during the COVID-19 pandemic: a cross-sectional internet survey. Therapeutic Adv. Musculoskelet. Disease. 12, 1759720x20966124 (2020).","journal-title":"Therapeutic Adv. Musculoskelet. Disease"},{"issue":"6","key":"6114_CR36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1080\/03009742.2023.2177383","volume":"52","author":"M Dehlin","year":"2023","unstructured":"Dehlin, M. et al. Sex and country differences in gout: cross-country comparison between Sweden and the UK. Scand. J. Rheumatol. 52(6), 673\u2013682 (2023).","journal-title":"Scand. J. Rheumatol."},{"issue":"10","key":"6114_CR37","doi-asserted-by":"publisher","first-page":"e622","DOI":"10.1016\/S2665-9913(23)00206-0","volume":"5","author":"MD Russell","year":"2023","unstructured":"Russell, M. D. et al. Gout incidence and management during the COVID-19 pandemic in england, UK: a nationwide observational study using opensafely. Lancet Rheumatol. 5(10), e622\u2013e632 (2023).","journal-title":"Lancet Rheumatol."},{"issue":"1","key":"6114_CR38","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13075-021-02461-7","volume":"23","author":"L Bai","year":"2021","unstructured":"Bai, L., Zhou, J. B., Zhou, T., Newson, R. B. & Cardoso, M. A. Incident gout and weight change patterns: A retrospective cohort study of US adults. Arthritis Res. Therapy. 23(1), 69 (2021).","journal-title":"Arthritis Res. Therapy"},{"issue":"11","key":"6114_CR39","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1136\/annrheumdis-2017-211472","volume":"76","author":"SM Nielsen","year":"2017","unstructured":"Nielsen, S. M. et al. Weight loss for overweight and obese individuals with gout: A systematic review of longitudinal studies. Ann. Rheum. Dis. 76(11), 1870\u20131882 (2017).","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"6114_CR40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/BOR.0b013e3283438e13","volume":"23","author":"JA Singh","year":"2011","unstructured":"Singh, J. A., Reddy, S. G. & Kundukulam, J. Risk factors for gout and prevention: A systematic review of the literature. Curr. Opin. Rheumatol. 23(2), 192\u2013202 (2011).","journal-title":"Curr. Opin. Rheumatol."},{"issue":"2","key":"6114_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1177\/10781552211029703","volume":"28","author":"J Kaur","year":"2022","unstructured":"Kaur, J., Tuler, S. & Dasanu, C. A. Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia. J. Oncol. Pharm. Practice: Official Publication Int. Soc. Oncol. Pharm. Practitioners. 28(2), 442\u2013444 (2022).","journal-title":"J. Oncol. Pharm. Practice: Official Publication Int. Soc. Oncol. Pharm. Practitioners"},{"issue":"6","key":"6114_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s11892-023-01506-2","volume":"23","author":"J Jiang","year":"2023","unstructured":"Jiang, J. et al. Prevalence of diabetes in patients with hyperuricemia and gout: A systematic review and Meta-analysis. Curr. Diab. Rep. 23(6), 103\u2013117 (2023).","journal-title":"Curr. Diab. Rep."},{"issue":"8","key":"6114_CR43","first-page":"472","volume":"151","author":"HJ Janssens","year":"2007","unstructured":"Janssens, H. J., van de Lisdonk, E. H., Janssen, M., van den Hoogen, H. J. & Verbeek, A. L. [Gout not induced by diuretics in a case-control study in general practice]. Ned. Tijdschr. Geneeskd. 151(8), 472\u2013477 (2007).","journal-title":"Ned. Tijdschr. Geneeskd."},{"key":"6114_CR44","doi-asserted-by":"publisher","first-page":"110466","DOI":"10.1016\/j.intimp.2023.110466","volume":"121","author":"W Liu","year":"2023","unstructured":"Liu, W. et al. Immune and inflammatory mechanisms and therapeutic targets of gout: an update. Int. Immunopharmacol. 121, 110466 (2023).","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"6114_CR45","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/nrrheum.2017.155","volume":"13","author":"AK So","year":"2017","unstructured":"So, A. K. & Martinon, F. Inflammation in gout: mechanisms and therapeutic targets. Nat. Rev. Rheumatol. 13(11), 639\u2013647 (2017).","journal-title":"Nat. Rev. Rheumatol."},{"key":"6114_CR46","doi-asserted-by":"publisher","first-page":"1137822","DOI":"10.3389\/fimmu.2023.1137822","volume":"14","author":"YR Liu","year":"2023","unstructured":"Liu, Y. R., Wang, J. Q. & Li, J. Role of NLRP3 in the pathogenesis and treatment of gout arthritis. Front. Immunol. 14, 1137822 (2023).","journal-title":"Front. Immunol."},{"issue":"5","key":"6114_CR47","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jbspin.2020.03.017","volume":"87","author":"R Sun","year":"2020","unstructured":"Sun, R. et al. Evaluation of febuxostat initiation during an acute gout attack: A prospective, randomized clinical trial. Joint Bone Spine. 87(5), 461\u2013466 (2020).","journal-title":"Joint Bone Spine"},{"issue":"2","key":"6114_CR48","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s10067-020-05215-z","volume":"40","author":"X Zhang","year":"2021","unstructured":"Zhang, X., Tang, Y., Wang, M., Wang, D. & Li, Q. The clinical efficacy of urate-lowering therapy in acute gout: A meta-analysis of randomized controlled trials. Clin. Rheumatol. 40(2), 701\u2013710 (2021).","journal-title":"Clin. Rheumatol."},{"issue":"12","key":"6114_CR49","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00296-016-3579-z","volume":"36","author":"F Eminaga","year":"2016","unstructured":"Eminaga, F., La-Crette, J., Jones, A. & Abhishek, A. Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol. Int. 36(12), 1747\u20131752 (2016).","journal-title":"Rheumatol. Int."},{"issue":"6","key":"6114_CR50","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1002\/acr.25309","volume":"76","author":"D Maher","year":"2024","unstructured":"Maher, D. et al. Comparative risk of gout flares when initiating or escalating various Urate-Lowering therapy: A systematic review with network Meta-Analysis. Arthritis Care Res. 76(6), 871\u2013881 (2024).","journal-title":"Arthritis Care Res."},{"issue":"12","key":"6114_CR51","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/ard-2023-224731","volume":"82","author":"L Stamp","year":"2023","unstructured":"Stamp, L. et al. Is Colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial. Ann. Rheum. Dis. 82(12), 1626\u20131634 (2023).","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"6114_CR52","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/acr.25376","volume":"76","author":"LK Stamp","year":"2024","unstructured":"Stamp, L. K. et al. Predicting gout flares in people starting allopurinol using the Start-Low Go-Slow dose escalation strategy. Arthritis Care Res. 76(10), 1371\u20131378 (2024).","journal-title":"Arthritis Care Res."},{"issue":"6","key":"6114_CR53","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/1756-185X.12648","volume":"18","author":"S Xu","year":"2015","unstructured":"Xu, S. et al. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int. J. Rheum. Dis. 18(6), 669\u2013678 (2015).","journal-title":"Int. J. Rheum. Dis."},{"issue":"7","key":"6114_CR54","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","volume":"56","author":"M Hui","year":"2017","unstructured":"Hui, M. et al. The British society for rheumatology guideline for the management of gout. Rheumatol. (Oxford England). 56(7), 1246 (2017).","journal-title":"Rheumatol. (Oxford England)"},{"issue":"6","key":"6114_CR55","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.41247","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald, J. D. et al. 2020 American college of rheumatology guideline for the management of gout. Arthritis Rheumatol. (Hoboken NJ). 72(6), 879\u2013895 (2020).","journal-title":"Arthritis Rheumatol. (Hoboken NJ)"},{"key":"6114_CR56","doi-asserted-by":"publisher","first-page":"152367","DOI":"10.1016\/j.semarthrit.2024.152367","volume":"65","author":"V Tai","year":"2024","unstructured":"Tai, V. et al. An updated systematic review and meta-analysis of randomised controlled trials on the effects of urate-lowering therapy initiation during a gout flare. Semin. Arthritis Rheum. 65, 152367 (2024).","journal-title":"Semin. Arthritis Rheum."},{"issue":"9","key":"6114_CR57","first-page":"533","volume":"102","author":"KT Clebak","year":"2020","unstructured":"Clebak, K. T., Morrison, A. & Croad, J. R. Gout: rapid evidence review. Am. Family Phys. 102(9), 533\u2013538 (2020).","journal-title":"Am. Family Phys."},{"issue":"2","key":"6114_CR58","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1136\/annrheumdis-2012-202589","volume":"73","author":"Y Zhang","year":"2014","unstructured":"Zhang, Y. et al. Low-dose aspirin use and recurrent gout attacks. Ann. Rheum. Dis. 73(2), 385\u2013390 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"6114_CR59","doi-asserted-by":"publisher","first-page":"1045561","DOI":"10.3389\/fphar.2022.1045561","volume":"13","author":"XF Jiao","year":"2022","unstructured":"Jiao, X. F. et al. Hyperuricaemia, gout and related adverse events associated with antihypertensive drugs: A real-world analysis using the FDA adverse event reporting system. Front. Pharmacol. 13, 1045561 (2022).","journal-title":"Front. Pharmacol."},{"key":"6114_CR60","doi-asserted-by":"publisher","first-page":"d8190","DOI":"10.1136\/bmj.d8190","volume":"344","author":"HK Choi","year":"2012","unstructured":"Choi, H. K., Soriano, L. C., Zhang, Y. & Rodr\u00edguez, L. A. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ (Clinical Res. ed). 344, d8190 (2012).","journal-title":"BMJ (Clinical Res. ed)"},{"issue":"1","key":"6114_CR61","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/art.38203","volume":"66","author":"S Bruderer","year":"2014","unstructured":"Bruderer, S., Bodmer, M., Jick, S. S. & Meier, C. R. Use of diuretics and risk of incident gout: A population-based case-control study. Arthritis Rheumatol. (Hoboken NJ). 66(1), 185\u2013196 (2014).","journal-title":"Arthritis Rheumatol. (Hoboken NJ)"},{"issue":"2","key":"6114_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/1526924820913514","volume":"30","author":"MD Brigham","year":"2020","unstructured":"Brigham, M. D. et al. Immunosuppressant use and gout in the prevalent solid organ transplantation population. Progress Transplantation (Aliso Viejo Calif). 30(2), 103\u2013110 (2020).","journal-title":"Progress Transplantation (Aliso Viejo Calif)"},{"issue":"32","key":"6114_CR63","doi-asserted-by":"publisher","first-page":"4161","DOI":"10.2174\/138161205774913309","volume":"11","author":"SS Daskalopoulou","year":"2005","unstructured":"Daskalopoulou, S. S., Tzovaras, V., Mikhailidis, D. P. & Elisaf, M. Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr. Pharm. Design. 11(32), 4161\u20134175 (2005).","journal-title":"Curr. Pharm. Design"},{"issue":"1","key":"6114_CR64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.21037\/atm-20-3458","volume":"9","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Survey on uric acid in Chinese subjects with essential hypertension (SUCCESS): A nationwide cross-sectional study. Annals Translational Med. 9(1), 27 (2021).","journal-title":"Annals Translational Med."},{"issue":"4","key":"6114_CR65","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1517\/14740338.2012.682981","volume":"11","author":"A Kei","year":"2012","unstructured":"Kei, A. & Elisaf, M. S. Nicotinic acid: clinical considerations. Exp. Opin. Drug Saf. 11(4), 551\u2013564 (2012).","journal-title":"Exp. Opin. Drug Saf."},{"issue":"11","key":"6114_CR66","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/j.1463-1326.2010.01289.x","volume":"12","author":"S Fazio","year":"2010","unstructured":"Fazio, S. et al. Long-term efficacy and safety of ezetimibe\/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes. Metab. 12(11), 983\u2013993 (2010).","journal-title":"Diabetes Obes. Metab."},{"issue":"14","key":"6114_CR67","doi-asserted-by":"publisher","first-page":"7567","DOI":"10.1039\/D4FO00987H","volume":"15","author":"HW Tao","year":"2024","unstructured":"Tao, H. W. et al. Lower plasma Linoleic acids as a risk factor for gout: An integrated analysis of population-based cohort and genetic data. Food Funct. 15(14), 7567\u20137576 (2024).","journal-title":"Food Funct."},{"issue":"5","key":"6114_CR68","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell, L. & Shakir, S. A. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 29(5), 385\u2013396 (2006).","journal-title":"Drug Saf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06114-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06114-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06114-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:03:28Z","timestamp":1751421808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06114-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6114"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06114-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. All data in this study were secondhand and derived from public databases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22856"}}